FI3661503T3 - PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ - Google Patents
PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ Download PDFInfo
- Publication number
- FI3661503T3 FI3661503T3 FIEP18755632.9T FI18755632T FI3661503T3 FI 3661503 T3 FI3661503 T3 FI 3661503T3 FI 18755632 T FI18755632 T FI 18755632T FI 3661503 T3 FI3661503 T3 FI 3661503T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- administered
- Prior art date
Links
- 230000002378 acidificating effect Effects 0.000 title 1
- 229940121375 antifungal agent Drugs 0.000 title 1
- 239000003429 antifungal agent Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 18
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 claims 1
- 210000003484 anatomy Anatomy 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541370P | 2017-08-04 | 2017-08-04 | |
| PCT/US2018/044619 WO2019028034A1 (en) | 2017-08-04 | 2018-07-31 | Antifungal agents with enhanced activity in acidic ph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3661503T3 true FI3661503T3 (fi) | 2022-12-15 |
Family
ID=63209698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18755632.9T FI3661503T3 (fi) | 2017-08-04 | 2018-07-31 | PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11534433B2 (https=) |
| EP (3) | EP4732902A2 (https=) |
| JP (1) | JP7214714B2 (https=) |
| KR (1) | KR102807716B1 (https=) |
| CN (2) | CN111093655A (https=) |
| AU (2) | AU2018309718B2 (https=) |
| BR (1) | BR112020002290A2 (https=) |
| CA (1) | CA3071940A1 (https=) |
| CY (1) | CY1125690T1 (https=) |
| DK (1) | DK3661503T3 (https=) |
| EA (1) | EA202090445A1 (https=) |
| ES (1) | ES2932658T3 (https=) |
| FI (1) | FI3661503T3 (https=) |
| HR (1) | HRP20221414T1 (https=) |
| HU (1) | HUE060508T2 (https=) |
| LT (1) | LT3661503T (https=) |
| MA (1) | MA49751B1 (https=) |
| MD (1) | MD3661503T2 (https=) |
| MX (1) | MX2020001399A (https=) |
| PL (1) | PL3661503T3 (https=) |
| PT (1) | PT3661503T (https=) |
| RS (1) | RS63746B1 (https=) |
| SI (1) | SI3661503T1 (https=) |
| SM (1) | SMT202200461T1 (https=) |
| TW (1) | TWI805600B (https=) |
| WO (1) | WO2019028034A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55081A (fr) * | 2019-02-27 | 2022-01-05 | Scynexis Inc | <smallcaps/>? ? ?pneumocystis? ? ? ? ?antifongiques triterpénoïdes pour le traitement ou la prévention de la pneumonie àspp |
| BR112021022876A2 (pt) * | 2019-05-16 | 2022-04-12 | Scynexis Inc | Método para descolonizar candida auris de uma área anatômica de um sujeito |
| WO2022140646A1 (en) * | 2020-12-26 | 2022-06-30 | Mycovia Pharmaceuticals, Inc | Dosing regimen for oteseconazole |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| DK2007396T3 (da) | 2006-04-03 | 2013-03-18 | Merck Sharp & Dohme | Enfumafungin-derivat som antimykotika |
| RS53731B1 (sr) * | 2008-08-12 | 2015-06-30 | Scynexis, Inc. | Antigljivični agensi |
| US8188085B2 (en) | 2008-08-12 | 2012-05-29 | Merck Sharp & Dohme Corp. | Antifungal agents |
| LT3247711T (lt) | 2015-01-19 | 2022-05-25 | Scynexis, Inc. | Naujos scy-078 druskos ir polimorfai |
| EP3609539A1 (en) * | 2017-04-10 | 2020-02-19 | Scynexis, Inc. | Antifungal agents used in combination |
-
2018
- 2018-07-31 EP EP25222120.5A patent/EP4732902A2/en active Pending
- 2018-07-31 MA MA49751A patent/MA49751B1/fr unknown
- 2018-07-31 CN CN201880059398.2A patent/CN111093655A/zh active Pending
- 2018-07-31 PT PT187556329T patent/PT3661503T/pt unknown
- 2018-07-31 EP EP18755632.9A patent/EP3661503B1/en not_active Revoked
- 2018-07-31 HR HRP20221414TT patent/HRP20221414T1/hr unknown
- 2018-07-31 SM SM20220461T patent/SMT202200461T1/it unknown
- 2018-07-31 CA CA3071940A patent/CA3071940A1/en active Pending
- 2018-07-31 FI FIEP18755632.9T patent/FI3661503T3/fi active
- 2018-07-31 KR KR1020207005972A patent/KR102807716B1/ko active Active
- 2018-07-31 US US16/636,230 patent/US11534433B2/en active Active
- 2018-07-31 RS RS20221058A patent/RS63746B1/sr unknown
- 2018-07-31 AU AU2018309718A patent/AU2018309718B2/en active Active
- 2018-07-31 DK DK18755632.9T patent/DK3661503T3/da active
- 2018-07-31 MD MDE20200607T patent/MD3661503T2/ro not_active IP Right Cessation
- 2018-07-31 PL PL18755632.9T patent/PL3661503T3/pl unknown
- 2018-07-31 ES ES18755632T patent/ES2932658T3/es active Active
- 2018-07-31 MX MX2020001399A patent/MX2020001399A/es unknown
- 2018-07-31 WO PCT/US2018/044619 patent/WO2019028034A1/en not_active Ceased
- 2018-07-31 SI SI201830810T patent/SI3661503T1/sl unknown
- 2018-07-31 JP JP2020505869A patent/JP7214714B2/ja active Active
- 2018-07-31 EA EA202090445A patent/EA202090445A1/ru unknown
- 2018-07-31 BR BR112020002290-0A patent/BR112020002290A2/pt not_active Application Discontinuation
- 2018-07-31 CN CN202410653474.XA patent/CN118542868A/zh active Pending
- 2018-07-31 LT LTEPPCT/US2018/044619T patent/LT3661503T/lt unknown
- 2018-07-31 EP EP22193944.0A patent/EP4169514B1/en active Active
- 2018-07-31 HU HUE18755632A patent/HUE060508T2/hu unknown
- 2018-08-03 TW TW107127013A patent/TWI805600B/zh active
-
2022
- 2022-11-18 US US17/990,656 patent/US20230364067A1/en not_active Abandoned
- 2022-12-06 CY CY20221100767T patent/CY1125690T1/el unknown
-
2024
- 2024-10-21 AU AU2024227501A patent/AU2024227501A1/en active Pending
- 2024-12-03 US US18/967,641 patent/US20260000656A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3661503T3 (fi) | PARANTUNEEN AKTIIVISUUDEN HAPPAMASSA pH:SSA OMAAVIA SIENILÄÄKKEITÄ | |
| HRP20231276T1 (hr) | Inhibitor egfr-a za liječenje raka | |
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| FI3805222T3 (fi) | 7-bentsyyli-4-(2-metyylibentsyyli)-2,4,6,7,8,9-heksahydroimidatso[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-onijohdannaisia, niiden suoloja ja niiden käyttö hoidossa | |
| HRP20120633T1 (hr) | Formulacija rasagilina s odgođenim oslobađanjem | |
| RU2011135417A (ru) | Галеновы препараты органических соединений | |
| IL298998B2 (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor | |
| Hu et al. | Discovery of a series of dihydroquinoxalin-2 (1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor | |
| AU712914B2 (en) | Antifungal composition | |
| Yang et al. | Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer | |
| JP2020529999A5 (https=) | ||
| EP2849747B1 (en) | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and a nsar | |
| CA2669853A1 (en) | Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | |
| WO2007016128A3 (en) | Magnesium salt proton pump inhibitor dosage forms | |
| JP2016505628A5 (https=) | ||
| CN104003948A (zh) | 一类氮唑类化合物及其制备方法和应用 | |
| JP2017057199A5 (https=) | ||
| RU2011134414A (ru) | Комбинация фульвовой кислоты для лечения различных состояний и болезней | |
| Zhu et al. | New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents | |
| US10463643B2 (en) | Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea | |
| SG193328A1 (en) | Solid preparation | |
| RU2005135207A (ru) | Способ профилактики осложнений химиотерапии при лечении онкологического заболевания | |
| HK1204939B (en) | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and meloxicam | |
| HK1204939A1 (en) | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano [3,4,b]indol]-4-amine and meloxicam | |
| CN101940788A (zh) | 抗抑郁药物在治疗应激性胃溃疡中的应用 |